Market Capitalization

As childhood nearsightedness soars, a new contact lens offers hope by not just correcting vision but actively slowing its progression in key global markets.

As Sri Lanka emerges from its economic crisis, a first-of-its-kind European-regulated fund provides a liquid, secure path to its undervalued assets.

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

As Prime Drink Group faces heavy losses, the appointment of water industry expert Germain Turpin as interim CEO signals a strategic pivot to its core assets.

The industrial fluids leader declared a steady dividend, reflecting financial discipline and confidence in its long-term strategy despite market headwinds.

The biotech firm's stock surged after announcing a massive share repurchase, a bold move balancing shareholder value with its high-stakes R&D pipeline.

A class action lawsuit alleges hospital operator Ardent Health misled investors by hiding financial risks, leading to a 33% stock price collapse.

Following a historic $2B revenue year, Tradeweb's CEO will address institutional investors, focusing on AI, digital assets, and global market expansion.

The natural gas producer raised its quarterly dividend by 11%, backed by strong earnings and a positive outlook despite volatile energy prices.

Treace Medical reports a Q4 revenue dip despite surgeon growth, revealing a strategic shift to lower-priced kits and a challenging 2026 outlook.

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

The Nordic tech firm shows signs of operational recovery and a promising AI strategy, but a mountain of debt and negative equity casts a long shadow.

Clipper Realty's Q4 results show a stark divide in NYC real estate, as soaring apartment rents struggle to offset deep losses from its troubled office portfolio.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

A Virginia tech firm's patent portfolio is valued at $18B, giving it foundational control over AI and 5G. What does this mean for the industry?

New research reveals a massive trust gap in healthcare AI as overall confidence drops. Why are users believers while the vast majority of Americans remain wary?

Heron Therapeutics posts record growth fueled by ZYNRELEF and APONVIE, issuing strong 2026 guidance and signaling a successful pivot to profitability.

With record SUBLOCADE revenue and a new U.S. home, Indivior launches a $400M buyback, signaling a new era in its fight against the opioid crisis.

The energy giant is using a complex financial tool to fund major projects. We break down what it means for investors and the future of the power grid.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.